\ European Commission Approves Expanded Indication For Amgen's XGEVAŽ (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma
Company News: Page (1) of 1 - 04/03/18

European Commission Approves Expanded Indication For Amgen's XGEVAŽ (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma

This Approval was Based on the Largest International Trial Ever Conducted for the Prevention of Skeletal-Related Events in Multiple Myeloma Patients

April 03, 2018 --
This article is no longer available,but here are some related topics.

Page: 1
Related Keywords:Manufacturing,Sales,Applications,Suppliers,Manufacturing/Production,Marketing,Insurance,Shipping & Receiving,Manufacturing,Sales & Marketing,Security,Database,Business Issues,Administration,Legal,Other,Management,Sales,Sales,USA,IT (Information Technology),Security,Medicine,Disease,Surgery,

Source:PR Newswire. All Rights Reserved

Our Privacy Policy --- @ Copyright, 2015 Digital Media Online, All Rights Reserved

Webmaster
Privacy.